KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 3,354 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 3,354 shares of the firm’s stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $15.70, for a total transaction of $52,657.80. Following the transaction, the chief executive officer directly owned 428,286 shares in the company, valued at $6,724,090.20. This trade represents a 0.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

KalVista Pharmaceuticals Price Performance

Shares of KALV opened at $14.91 on Friday. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The company’s fifty day moving average price is $15.63 and its 200-day moving average price is $13.82. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00. The firm has a market capitalization of $753.70 million, a PE ratio of -3.77 and a beta of -0.19.

Analyst Ratings Changes

Several analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Needham & Company LLC raised their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Citizens Jmp lowered their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company boosted its position in KalVista Pharmaceuticals by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after acquiring an additional 818 shares during the last quarter. BNP Paribas Financial Markets increased its stake in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Rhumbline Advisers lifted its position in KalVista Pharmaceuticals by 2.8% during the second quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after buying an additional 1,458 shares during the period. Police & Firemen s Retirement System of New Jersey grew its holdings in KalVista Pharmaceuticals by 26.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock valued at $110,000 after buying an additional 2,061 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of KalVista Pharmaceuticals by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock valued at $5,239,000 after acquiring an additional 2,402 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.